scholarly journals The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians

Oncotarget ◽  
2018 ◽  
Vol 9 (40) ◽  
pp. 26217-26225 ◽  
Author(s):  
Katharina C. Kähler ◽  
Christine Blome ◽  
Andrea Forschner ◽  
Ralf Gutzmer ◽  
Axel Hauschild ◽  
...  
Keyword(s):  
Interferon Therapy ◽  
Risk Of Recurrence ◽  
Melanoma Patients ◽  
Adjuvant Interferon ◽  
Versus Risk

scholarly journals Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial

2010 ◽  
Vol 8 (1) ◽  
Author(s):  
Helen Gogas ◽  
Urania Dafni ◽  
Henry Koon ◽  
Maria Spyropoulou-Vlachou ◽  
Yannis Metaxas ◽  
...  
Keyword(s):  
High Risk ◽  
Interferon Therapy ◽  
Multicenter Trial ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Melanoma Patients ◽  
Adjuvant Interferon

Tyrosinase mRNA in Blood of Patients With Melanoma Treated With Adjuvant Interferon

2002 ◽  
Vol 20 (19) ◽  
pp. 4032-4039 ◽  
Author(s):  
Begoña Mellado ◽  
Maria del Carmen Vela ◽  
Dolors Colomer ◽  
Lorena Gutierrez ◽  
Teresa Castel ◽  
...  
Keyword(s):  
Interferon Therapy ◽  
Surrogate Marker ◽  
Disease Free Survival ◽  
Melanoma Cells ◽  
Interferon Response ◽  
Interferon Treatment ◽  
Rt Pcr ◽  
Melanoma Patients ◽  
Adjuvant Interferon

PURPOSE: To evaluate the clinical significance of the detection of circulating melanoma cells in patients treated with adjuvant interferon and to determine their potential value as a marker of interferon response. PATIENTS AND METHODS: We prospectively analyzed 616 peripheral-blood samples from 120 melanoma patients with stage IIA (n = 33), IIB (n = 22), III (n = 50), or IV (surgically resected) (n = 15) disease receiving adjuvant interferon alfa-2b therapy. Tyrosinase mRNA was assayed by reverse transcriptase polymerase chain reaction (RT-PCR) as a marker of circulating melanoma cells before the start of interferon and every 2 to 3 months thereafter. RESULTS: With a median follow-up time of 32.3 months (range, 7.1 to 77.5 months), 47 patients (39.8%) relapsed and 31 (26%) died. During adjuvant interferon treatment, 76 patients (64%) had undetected circulating melanoma cells and 44 patients (36%) had a positive RT-PCR result in at least one sample. Actuarial 5-year disease-free survival was 62% in patients with persistently negative RT-PCR during interferon treatment and 38% for patients with positive RT-PCR during interferon (P = .02). Actuarial 5-year overall survival was 75% and 50%, respectively (P = .03). CONCLUSION: Patients with melanoma and tyrosinase mRNA detected in the blood during adjuvant interferon therapy had a worse prognosis compared with patients with undetected tyrosinase mRNA during treatment. Further investigation into the detection of circulating melanoma cells as a surrogate marker of response to adjuvant interferon therapy is warranted.

Prognostic value of serum YKL-40 in stage IIB-III melanoma patients receiving adjuvant interferon therapy.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 8587-8587 ◽  
Author(s):  
M. Krogh ◽  
I. J. Christensen ◽  
M. Bouwhuis ◽  
J. S. Johansen ◽  
H. Schmidt ◽  
...  
Keyword(s):  
Prognostic Value ◽  
Interferon Therapy ◽  
Melanoma Patients ◽  
Adjuvant Interferon

Autoimmune phenomena as prognostic markers of response to adjuvant interferon therapy for melanoma

2007 ◽  
Vol 9 (3) ◽  
pp. 125-126
Author(s):  
J. Puente Vázquez ◽  
J. L. González Larriba
Keyword(s):  
Interferon Therapy ◽  
Prognostic Markers ◽  
Autoimmune Phenomena ◽  
Adjuvant Interferon

9341 Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon a (EORTC 18952) have no prognostic value on treatment outcome

2009 ◽  
Vol 7 (2) ◽  
pp. 589
Author(s):  
M.G. Bouwhuis ◽  
S. Collette ◽  
S. Suciu ◽  
A.J.G. Swaak ◽  
W.H. Kruit ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Prognostic Value ◽  
Melanoma Patients ◽  
Adjuvant Interferon

P-18 Autoimmune disease during adjuvant interferon therapy in patients with malignant melanoma

2004 ◽  
Vol 14 (4) ◽  
pp. A22
Author(s):  
M. Karaoli ◽  
T. Petrakopoulou ◽  
N. Pergantas ◽  
P. Balgouranoudi ◽  
A. Yiacoumettis
Keyword(s):  
Malignant Melanoma ◽  
Autoimmune Disease ◽  
Interferon Therapy ◽  
Adjuvant Interferon

scholarly journals Recurrent Pericarditis, an Unexpected Effect of Adjuvant Interferon Chemotherapy for Malignant Melanoma

2016 ◽  
Vol 2016 ◽  
pp. 1-3 ◽  
Author(s):  
Farhan Ashraf ◽  
Fady Marmoush ◽  
Muhammad Ismail Shafi ◽  
Ashish Shah
Keyword(s):  
Adjuvant Chemotherapy ◽  
Malignant Melanoma ◽  
Interferon Therapy ◽  
Young Female ◽  
Good Effect ◽  
Recurrent Pericarditis ◽  
Drug Induced ◽  
Cardiac Pathology ◽  
Adjuvant Interferon

Drug-induced pericarditis is a well-described cardiac pathology that can result from a variety of medications; however, interferon-mediated pericarditis is extremely rare. We present a case of a young female with recurrent pericarditis due to interferon therapy. The role of interferon in adjuvant chemotherapy is well known and yields good effect, but this case highlights the very uncommon phenomena of interferon induced pericarditis and the significant distress it can cause.

scholarly journals PCN11: COST-EFFECTIVENESS OF SENTINEL LYMPH NODE MAPPING AND ADJUVANT INTERFERON THERAPY FOR STAGE II MELANOMA

2001 ◽  
Vol 4 (6) ◽  
pp. 435
Author(s):  
LS Wilson ◽  
CM Reyes ◽  
C Lu ◽  
M Lu ◽  
C Yen
Keyword(s):  
Lymph Node ◽  
Cost Effectiveness ◽  
Sentinel Lymph Node ◽  
Interferon Therapy ◽  
Sentinel Lymph Node Mapping ◽  
Stage Ii ◽  
Lymph Node Mapping ◽  
Adjuvant Interferon

Correlation of molecular HLA typing and outcome in high-risk melanoma patients receiving adjuvant interferon

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 8029-8029
Author(s):  
H. Gogas ◽  
M. Spyropoulou-Vlachou ◽  
U. Dafni ◽  
D. Tsoutsos ◽  
C. Markopoulos ◽  
...  
Keyword(s):  
High Risk ◽  
Hla Class I ◽  
Antigen Expression ◽  
Class I ◽  
Healthy Controls ◽  
High Risk Melanoma ◽  
Risk Melanoma ◽  
Melanoma Patients ◽  
Adjuvant Interferon ◽  
Group 1

8029 Background: Serological typing for both HLA class I and class II antigen expression, has previously shown association of specific HLA antigen expression with clinical response and survival in patients with metastatic melanoma treated with IL-2 (e.g. HLA-DQ1). Purpose: To evaluate the impact of HLA class I (low-resolution) and class II (high-resolution) expression, on the outcome of high-risk melanoma patients receiving adjuvant high-dose interferon. Methods: 181 stage IIB, IIC and III melanoma patients (88 female and 93 male), median age 52.1 years and 246 healthy controls were included in this study. DNA was used for the determination of HLA-A, HLA-B, HLA-Cw, HLA-DRB1 and HLA-DQB1 genotypes. Results: With a median follow-up of 37 months, 59 (group 1) patients have remained with no evidence of recurrence and 122 have recurred (group 2). Statistical significant differences between the two groups, were found in the following genotypes: HLA-A*02 (42% vs. 57.3%, p=0.08), HLA-A*33 (15.2% vs. 6.5%, p=0.05), HLA-B*51 (15.2% vs. 34.4%, p=0.01), HLA-B*57 (11.8% vs. 2.4%, p=0.02). Statistical significant differences between group 1 and healthy controls, were found in the following genotypes: HLA-A*33 (15.2% vs. 6.5%, p=0.05), HLA-B*51 (15.2% vs. 28.5%, p=0.05), HLA-B*57 (11.8% vs. 4.5%, p=0.05), HLA-Cw*03 (23.7% vs. 11%, p=0.01), HLA-Cw*06 (27.1% vs. 16.1%, p=0.06), HLA-DRB1*0701 (27.1% vs. 13.4%, p=0.01), HLA-DRB1*1601 (35.6% vs. 22.3%, p=0.01), HLA-DQB1*0202 (23.8% vs. 10.1%, p=0.09). Conclusions: Statistical significant differences were seen in HLA-A and HLA-B alleles between the patients with high-risk melanoma free of recurrence and those who recurred after treatment with adjuvant interferon. Additionally, differences were seen between healthy controls and melanoma patients free of recurrence. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document